Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

F. Iommelli, V. De Rosa, R. Fonti, S. Del Vecchio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Advancing knowledge of non-small cell lung cancer (NSCLC) has provided new treatment options based on the specific gene alterations found in individual tumors. The presence of activating mutations in the epidermal growth factor receptor (EGFR) in NSCLC is strongly associated with a high sensitivity to EGFR tyrosine kinase inhibitors (TKIs) and is also a criterion used to identify candidates for first-line therapy with these drugs among patients with advanced disease. However, acquired resistance to EGFR TKIs invariably emerges over time due in part to secondary mutations in EGFR or redundant lateral signaling. Molecular imaging, allowing the visualization of cellular processes and their modulation by both conventional anticancer drugs and molecularly targeted agents, may be effectively used in NSCLC patients during treatment with EGFR TKIs. In particular, positron emission tomography with 18F-FDG and 18F-FLT has been performed in both preclinical and clinical settings to distinguish treatment-sensitive from treatment-resistant NSCLCs. Here we provide a short overview of the mechanisms underlying sensitivity and resistance of NSCLCs to EGFR TKIs and then focus on the contribution that molecular imaging can make to the development of tailored therapy in NSCLC patients.

Original languageEnglish
Pages (from-to)43-53
Number of pages11
JournalClinical and Translational Imaging
Volume2
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Molecular Imaging
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Mutation
Fluorodeoxyglucose F18
Positron-Emission Tomography
Drug Therapy
Pharmaceutical Preparations
Genes
Neoplasms

Keywords

  • EGFR
  • Lung cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. / Iommelli, F.; De Rosa, V.; Fonti, R.; Del Vecchio, S.

In: Clinical and Translational Imaging, Vol. 2, No. 1, 2014, p. 43-53.

Research output: Contribution to journalArticle

@article{99a630b58ddd4a288923f01c31aa4013,
title = "Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer",
abstract = "Advancing knowledge of non-small cell lung cancer (NSCLC) has provided new treatment options based on the specific gene alterations found in individual tumors. The presence of activating mutations in the epidermal growth factor receptor (EGFR) in NSCLC is strongly associated with a high sensitivity to EGFR tyrosine kinase inhibitors (TKIs) and is also a criterion used to identify candidates for first-line therapy with these drugs among patients with advanced disease. However, acquired resistance to EGFR TKIs invariably emerges over time due in part to secondary mutations in EGFR or redundant lateral signaling. Molecular imaging, allowing the visualization of cellular processes and their modulation by both conventional anticancer drugs and molecularly targeted agents, may be effectively used in NSCLC patients during treatment with EGFR TKIs. In particular, positron emission tomography with 18F-FDG and 18F-FLT has been performed in both preclinical and clinical settings to distinguish treatment-sensitive from treatment-resistant NSCLCs. Here we provide a short overview of the mechanisms underlying sensitivity and resistance of NSCLCs to EGFR TKIs and then focus on the contribution that molecular imaging can make to the development of tailored therapy in NSCLC patients.",
keywords = "EGFR, Lung cancer",
author = "F. Iommelli and {De Rosa}, V. and R. Fonti and {Del Vecchio}, S.",
year = "2014",
doi = "10.1007/s40336-014-0050-6",
language = "English",
volume = "2",
pages = "43--53",
journal = "Clinical and Translational Imaging",
issn = "2281-5872",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

AU - Iommelli, F.

AU - De Rosa, V.

AU - Fonti, R.

AU - Del Vecchio, S.

PY - 2014

Y1 - 2014

N2 - Advancing knowledge of non-small cell lung cancer (NSCLC) has provided new treatment options based on the specific gene alterations found in individual tumors. The presence of activating mutations in the epidermal growth factor receptor (EGFR) in NSCLC is strongly associated with a high sensitivity to EGFR tyrosine kinase inhibitors (TKIs) and is also a criterion used to identify candidates for first-line therapy with these drugs among patients with advanced disease. However, acquired resistance to EGFR TKIs invariably emerges over time due in part to secondary mutations in EGFR or redundant lateral signaling. Molecular imaging, allowing the visualization of cellular processes and their modulation by both conventional anticancer drugs and molecularly targeted agents, may be effectively used in NSCLC patients during treatment with EGFR TKIs. In particular, positron emission tomography with 18F-FDG and 18F-FLT has been performed in both preclinical and clinical settings to distinguish treatment-sensitive from treatment-resistant NSCLCs. Here we provide a short overview of the mechanisms underlying sensitivity and resistance of NSCLCs to EGFR TKIs and then focus on the contribution that molecular imaging can make to the development of tailored therapy in NSCLC patients.

AB - Advancing knowledge of non-small cell lung cancer (NSCLC) has provided new treatment options based on the specific gene alterations found in individual tumors. The presence of activating mutations in the epidermal growth factor receptor (EGFR) in NSCLC is strongly associated with a high sensitivity to EGFR tyrosine kinase inhibitors (TKIs) and is also a criterion used to identify candidates for first-line therapy with these drugs among patients with advanced disease. However, acquired resistance to EGFR TKIs invariably emerges over time due in part to secondary mutations in EGFR or redundant lateral signaling. Molecular imaging, allowing the visualization of cellular processes and their modulation by both conventional anticancer drugs and molecularly targeted agents, may be effectively used in NSCLC patients during treatment with EGFR TKIs. In particular, positron emission tomography with 18F-FDG and 18F-FLT has been performed in both preclinical and clinical settings to distinguish treatment-sensitive from treatment-resistant NSCLCs. Here we provide a short overview of the mechanisms underlying sensitivity and resistance of NSCLCs to EGFR TKIs and then focus on the contribution that molecular imaging can make to the development of tailored therapy in NSCLC patients.

KW - EGFR

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84907912483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907912483&partnerID=8YFLogxK

U2 - 10.1007/s40336-014-0050-6

DO - 10.1007/s40336-014-0050-6

M3 - Article

AN - SCOPUS:84907912483

VL - 2

SP - 43

EP - 53

JO - Clinical and Translational Imaging

JF - Clinical and Translational Imaging

SN - 2281-5872

IS - 1

ER -